Skip to content
Screener

Perspective Therapeutics CATX Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$31K-44.6%
Immunome logo
ImmunomeIMNM
$5.42M+24.6%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$59.72M+64.1%
uniQure logo
uniQureQURE
Tango Therapeutics logo
Tango TherapeuticsTNGX

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$29.3M-21.7%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
CapEx$14.2M+1,284%
Free cash flow-$34.8M-66.1%

Valuation

See full
Market cap$342.14M+25.3%
Enterprise value$297.56M+20.1%

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0.0×
Current ratio6.6×-8.5×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342512
Line itemJune 30, 2026December 31, 2025
Property and equipment, net107,79776,597
Right-of-use asset2,1961,500
Intangible assets, in-process research and development40,00040,000
Other assets509486
Total assets$392,025$266,972
LIABILITIES AND STOCKHOLDERSʼ EQUITY
Current liabilities:
Accounts payable and accrued expenses$29,418$20,511

ITEM 1 - FINANCIAL STATEMENTS

FAQ

What is Perspective Therapeutics's deferred tax assets and other non-current assets?
Perspective Therapeutics (CATX) reported deferred tax assets and other non-current assets of $509K in Q2 2026.
How has Perspective Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
Perspective Therapeutics's deferred tax assets and other non-current assets increased by 26.9% year-over-year, from $401K to $509K.
What is the long-term trend for Perspective Therapeutics's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Perspective Therapeutics's deferred tax assets and other non-current assets has grown at a 32.5% compound annual growth rate (CAGR), from $119K to $486K.
What does deferred tax assets and other non-current assets mean?
Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.

Ask your AI about Perspective Therapeutics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude